MKI67 and neoplasm: By contrast, in the neoadjuvant setting, a study consisted of 109 patients, suggested that high BMI might be a positive predictor of AI (exemestane) response based on tumor reduction rate, and another recent study found no difference in Ki67 changes and radiological response according to BMI19,20.